tolerability and adverse drug reactions of antiepileptic drugs

  • Research type

    Research Study

  • Full title

    effectiveness, tolerability and adverse drug reactions of antiepileptic drugs used in newly diagnosed patients: retrospective observational study

  • IRAS ID

    214663

  • Contact name

    Bshra Alsfouk

  • Contact email

    b.alsfouk.1@research.gla.ac.uk

  • Sponsor organisation

    NHS GGC

  • Duration of Study in the UK

    1 years, 6 months, 1 days

  • Research summary

    This is a retrospective review of routine clinical data.
    This project focuses mainly on adverse drug reaction of the antiepileptic drugs but it links to the efficacy as well. Adverse drug reaction is a major cause of the treatment failure. As they result in the initial discontinuation of the antiepileptic drug in 20% of the patients, impose a negative impact on patient adherence and prevent the usage of the fully therapeutic dosage.
    The aims of our study include evaluating the long-term efficacy and tolerability of the antiepileptic drugs and assessing the potential factors that influence the treatment outcomes. Most newer antiepileptuic drugs were reported to have equivalent efficacy to the established agents but have favourable safety profiles in clinical trials. Therefore, tolerability is the fundamental factor in antiepileptic drug selecting.
    We plan to use the clinical records maintained by the epilepsy unit of NHSGGC retrospectively to review all newly diagnosed epilepsy patients who start antiepileptic drugs and followed-up for at least one year after commencing the therapy. A total of 1528 eligible patients will be included in the study. We plan to complete the study within a period of 18 months.

  • REC name

    Yorkshire & The Humber - Bradford Leeds Research Ethics Committee

  • REC reference

    16/YH/0513

  • Date of REC Opinion

    14 Dec 2016

  • REC opinion

    Favourable Opinion